883547-44-2

Usage

Uses

Used in Medicinal Chemistry:
1-(3-M-TOLYL-[1,2,4]OXADIAZOL-5-YL)-ETHYLAMINE is used as a potential drug molecule in the field of medicinal chemistry for its unique structural features. The presence of the oxadiazole ring and the 3-methylphenyl group, along with the ethylamine side chain, may endow the compound with specific biological and pharmacological properties that could be harnessed for therapeutic applications.
Used in Pharmaceutical Research:
In the realm of pharmaceutical research, 1-(3-M-TOLYL-[1,2,4]OXADIAZOL-5-YL)-ETHYLAMINE is utilized as a compound of interest for further investigation. Its structure suggests that it may possess valuable properties for drug development, and additional research and testing are required to fully understand its potential applications and mechanisms of action.

InChI:InChI=1/C11H13N3O/c1-7-4-3-5-9(6-7)10-13-11(8(2)12)15-14-10/h3-6,8H,12H2,1-2H3

Upstream product

• 620-22-4 3-Methylbenzonitrile 
• 40067-82-1 N'-hydroxy-3-methylbenzimidamide 

Relevant academic research and scientific papers

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and in Vivo Activity of an Oxadiazole Series

The gene KCNT1 encodes the sodium-activated potassium channel KNa1.1 (Slack, Slo2.2). Variants in the KCNT1 gene induce a gain-of-function (GoF) phenotype in ionic currents and cause a spectrum of intractable neurological disorders in infants and children, including epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Effective treatment options for KCNT1-related disease are absent, and novel therapies are urgently required. We describe the development of a novel class of oxadiazole KNa1.1 inhibitors, leading to the discovery of compound 31 that reduced seizures and interictal spikes in a mouse model of KCNT1 GoF.

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.